

PRODUCT INFORMATION



Paricalcitol

Item No. 17716

CAS Registry No.: 131918-61-1

Formal Name: (1R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-1,3-cyclohexanediol

Synonyms: 1 α ,25-Dihydroxy-19-nor-vitamin D₂,
19-nor-1,25-Dihydroxyvitamin D₂,
Zemplar

MF: C₂₇H₄₄O₃

FW: 416.6


Purity: ≥98%

UV/Vis.: λ_{max}: 243, 251, 261 nm

Supplied as: A crystalline solid

Storage: -80°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Paricalcitol is supplied as a crystalline solid. A stock solution may be made by dissolving the paricalcitol in the solvent of choice, which should be purged with an inert gas. Paricalcitol is soluble in the organic solvent ethanol at a concentration of approximately 1 mg/ml.

Description

Paricalcitol is a synthetic 1,25-dihydroxy vitamin D₂ analog. As vitamin D deficiency, associated with chronic kidney disease, leads to an increase in parathyroid hormone (secondary hyperparathyroidism), paricalcitol is used in renal patients to block parathyroid hormone overproduction.¹⁻³ Vitamin D deficiency is also a risk factor in cancer, cardiovascular disease, hypertension, and diabetes, and paricalcitol may have applications in those contexts as well.⁴

References

1. Brown, A.J., Finch, J., Takahashi, F., *et al.* Calcemic activity of 19-nor-1,25(OH)₂D₂ decreases with duration of treatment. *J. Am. Soc. Nephrol.* **11**(11), 2088-2094 (2000).
2. Donate-Correa, J., Domínguez-Pimentel, V., Muros-de-Fuentes, M., *et al.* Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease. *Curr. Drug Targets* **15**(7), 703-709 (2014).
3. Walf, M. and Thadhani, R. Vitamin D in patients with renal failure: A summary of observational mortality studies and steps moving forward. *J. Steroid Biochem. Mol. Biol.* **103**(3-5), 487-490 (2007).
4. Duplancic, D., Cesarik, M., Poljak, N.K., *et al.* The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection. *Clin. Interv. Aging* **8**, 149-156 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/13/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM